Figure 1.
Conditioning regimen and engraftment. (A) Study schema. Peri-HCT ruxolitinib administration was from day −3 pre-HCT to day +30 post-HCT. Neutrophil (B) and platelet (C) engraftment post-HCT. aGVHD, acute GVHD; PO, orally; QD, once daily.
Conditioning regimen and engraftment. (A) Study schema. Peri-HCT ruxolitinib administration was from day −3 pre-HCT to day +30 post-HCT. Neutrophil (B) and platelet (C) engraftment post-HCT. aGVHD, acute GVHD; PO, orally; QD, once daily.